Day One Acquires Mersana for $285M to Gain Emi-Le Cancer Drug
Day One is acquiring Mersana Therapeutics for up to $285 million to gain Emi-Le, a promising new drug candidate for adenoid cystic carcinoma, a cancer with few treatment options.
/ 1 item
#MRSN↓